Top Anti Cancer Imported Medicine Drugs in India - Pharma Five

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Buy Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin) Medicine in India

Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin)

Medicine name : Keytruda / Keytruda SC (with Padcev)

Generic name : Pembrolizumab + Enfortumab Vedotin

Manufactured By : Merck & Co. (MSD) / Astellas-Pfizer (Padcev)

Indications : Perioperative treatment of adults with resectable muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility.

Medicine Description : A combination therapy for adults with resectable muscle-invasive bladder cancer (MIBC). Keytruda (Pembrolizumab) blocks PD-1 to enhance immune system activity, while Padcev (Enfortumab Vedotin) delivers targeted anticancer treatment to Nectin-4-expressing cancer cells. The combination is used as perioperative treatment before and after surgery.

Product Introduction

Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin) is a combination cancer treatment used for adults with resectable muscle-invasive bladder cancer (MIBC). It is administered as perioperative treatment, meaning it is given before surgery (neoadjuvant treatment) and continued after bladder removal surgery (adjuvant treatment). The FDA-approved indication covers eligible patients regardless of their cisplatin eligibility.

Pembrolizumab is an immunotherapy medicine that blocks the PD-1 pathway, helping the immune system recognise and attack cancer cells. Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4 on cancer cells and delivers a cell-killing agent. Together, these medicines help the immune system fight cancer while directly targeting cancer cells.

Common side effects may include fatigue, skin rash, itching, peripheral neuropathy, diarrhoea, nausea, decreased appetite, hair loss, changes in taste and abnormal liver or kidney test results. Serious risks include severe skin reactions, high blood sugar, lung inflammation, immune-mediated organ complications and nerve damage. Regular medical monitoring is essential throughout treatment.

Uses Of Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin)

Treatment of Resectable Muscle-Invasive Bladder Cancer (MIBC)

Benefits Of Keytruda / Keytruda SC (with Padcev)

Used as perioperative combination treatment for adults with resectable muscle-invasive bladder cancer. It is administered before surgery and continued after surgery to help reduce the risk of cancer recurrence, regardless of cisplatin eligibility.

Side Effects Of Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin)

Some patients may experience side effects during treatment with Keytruda / Keytruda SC (with Padcev). The severity may vary depending on individual health and treatment response.

Common Side Effects of Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin)

  • Skin rash
  • Peripheral neuropathy (tingling or numbness in hands and feet)
  • Fatigue
  • Itching
  • Diarrhoea
  • Hair loss
  • Weight loss
  • Decreased appetite
  • Nausea
  • Urinary tract infections
How To Use Keytruda / Keytruda SC (with Padcev)

This combination is administered under the supervision of an experienced oncology specialist. Enfortumab vedotin (Padcev) is given as an intravenous infusion over approximately 30 minutes on Days 1 and 8 of each 21-day cycle. Pembrolizumab is administered according to the prescribed formulation and schedule. For perioperative treatment of muscle-invasive bladder cancer, treatment is given before bladder removal surgery and continued afterwards. The number of cycles and treatment duration depend on cisplatin eligibility, the treatment plan and the patient's response.

How Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin) Works

Pembrolizumab blocks the PD-1 pathway, helping the immune system recognise and attack cancer cells. Enfortumab vedotin targets a protein called Nectin-4 found on many bladder cancer cells and delivers a cell-killing medicine into them. These complementary actions help the immune system fight cancer while directly damaging cancer cells.

Storage Conditions
  • Store unopened vials in a refrigerator at 2°C to 8°C in the original carton to protect from light.
  • Keep both medicines in their original cartons to protect them from light.
  • Do not freeze or shake the medicine vials.
  • Store prepared solutions according to the manufacturer's instructions and use them within the specified stability period.
Safety Advice

AlcoholAlcohol CONSULT YOUR DOCTOR

Avoid or limit alcohol consumption during treatment. Discuss drinking with your oncologist, particularly if you develop liver-related side effects or other treatment complications.

PregnancyPregnancy CONSULT YOUR DOCTOR

This combination may cause harm to an unborn baby. Pregnancy should be avoided during treatment. Women of reproductive potential should use effective contraception during treatment and for 4 months after the last pembrolizumab dose.

BreastfeedingBreastfeeding CONSULT YOUR DOCTOR

Breastfeeding is not recommended during treatment and for 4 months after the last pembrolizumab dose because of the potential risk of serious adverse reactions in the infant.

DrivingDriving CONSULT YOUR DOCTOR

Use caution when driving or operating machinery, as fatigue, dizziness, vision changes or peripheral neuropathy may affect your ability to do so safely.

KidneyKidney CAUTION

Inform your doctor if you have kidney problems. Kidney function should be monitored during treatment, and dose or treatment adjustments may be needed depending on your condition.

LiverLiver CAUTION

Inform your doctor about any existing liver disease. Liver function should be monitored regularly. Enfortumab vedotin should be avoided in patients with moderate or severe hepatic impairment.

Quick Tips
  • Receive treatment only under the supervision of an experienced oncology specialist.
  • Attend all scheduled infusions, medical appointments and laboratory tests.
  • Report skin rashes, numbness, tingling or changes in vision to your doctor promptly.
  • Seek immediate medical attention for breathing difficulties, severe diarrhoea or signs of high blood sugar.
  • Use effective contraception during treatment and follow your doctor's guidance on pregnancy and breastfeeding precautions.
  • Read More About - Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin) from Pharma Five.
About Pharma Five

Pharma Five assists patients in facilitating the import of limited quantities of Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin) for personal medical use, subject to applicable government regulations and import requirements. A valid prescription from a registered medical practitioner, Form 12A and other supporting documents may be required, depending on the applicable regulations.

With over 20 years of experience in the pharmaceutical industry, Pharma Five provides pharmaceutical consultancy and import assistance. We help patients understand the documentation and procedures involved in accessing Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin) for personal medical use. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

References
  1. https://go.drugbank.com/drugs/DB09037
  2. https://go.drugbank.com/drugs/DB13007
  3. https://www.fda.gov/drugs/cancer-approvals/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin
Faq

General Question

Keytruda / Keytruda SC (with Padcev) (Pembrolizumab + Enfortumab Vedotin) is a combination cancer treatment used for adults with muscle-invasive bladder cancer. It combines pembrolizumab immunotherapy with enfortumab vedotin, an antibody-drug conjugate.

Pembrolizumab blocks the PD-1 pathway, helping the immune system recognise and attack cancer cells. Enfortumab vedotin targets Nectin-4 on cancer cells and delivers a cell-killing medicine into them.

This combination is prescribed for eligible adults with muscle-invasive bladder cancer who are candidates for bladder removal surgery. Treatment suitability is determined by an oncologist based on the patient’s condition and treatment plan.

The treatment is administered by healthcare professionals. Enfortumab vedotin is given as an intravenous infusion, while pembrolizumab is administered using the prescribed intravenous or approved subcutaneous formulation and schedule.

Common side effects may include skin rash, peripheral neuropathy, fatigue, itching, diarrhoea, hair loss, nausea, decreased appetite, weight loss and urinary tract infections.

Yes. Serious side effects may include severe skin reactions, high blood sugar, lung inflammation, nerve damage and immune-related complications affecting organs such as the liver, kidneys and intestines. Contact your healthcare provider promptly if you notice unusual or severe symptoms.

Treatment duration depends on the treatment phase, cisplatin eligibility, response and tolerability. It may be given before surgery and continued after surgery according to the oncologist’s prescribed schedule.

There is no specific universal alcohol restriction, but alcohol consumption should be discussed with the treating oncologist. Avoid alcohol if advised, particularly if liver-related problems or other treatment complications develop.

This combination may cause harm to an unborn baby. Pregnancy should be avoided during treatment and effective contraception should be used during treatment and for 4 months after the last pembrolizumab dose.

Yes. Always inform your oncologist about prescription medicines, over-the-counter products, vitamins and herbal supplements. Some medicines may affect treatment safety or increase the risk of side effects.

Contact your oncology treatment team as soon as possible for instructions if an appointment or dose is missed. Do not take an extra dose or change the treatment schedule yourself.

Food does not directly affect the administration of this treatment because it is given by infusion or injection rather than taken as an oral medicine. Follow your healthcare provider’s dietary advice.

Attend all scheduled appointments and blood tests. Report skin changes, numbness, tingling, breathing difficulties, severe diarrhoea, vision changes or symptoms of high blood sugar promptly. Do not stop or alter treatment without medical advice.

Store unopened Keytruda and Padcev vials in a refrigerator at 2°C to 8°C in their original cartons to protect them from light. Do not freeze or shake the vials. Follow the product-specific instructions for prepared solutions.

Pharma Five may assist with information and import facilitation for personal medical use, subject to applicable regulations and required documentation. A valid prescription and supporting documents may be required. Pharma Five assists in its procurement.

Timely Service
Doorstep Delivery
Hassle-Free Process
100% Genuine Sources